Skip to main content

Articles

Page 10 of 26

  1. To establish and validate 18F-fluorodeoxyglucose (18F-FDG) PET/CT-based radiomics model and use it to predict the intermediate-high risk growth patterns in early invasive adenocarcinoma (IAC).

    Authors: Xiaonan Shao, Rong Niu, Xiaoliang Shao, Zhenxing Jiang and Yuetao Wang
    Citation: EJNMMI Research 2020 10:80
  2. The therapeutic use of [131I]meta-iodobenzylguanidine ([131I]MIBG) is often accompanied by hematological toxicity, mainly consisting of persistent and severe thrombocytopenia. While MIBG accumulates in neuroblast...

    Authors: Thomas Blom, Rutger Meinsma, Marja Rutgers, Corine Buitenhuis, Marieke Dekken-Van den Burg, André B. P. van Kuilenburg and Godelieve A. M. Tytgat
    Citation: EJNMMI Research 2020 10:78
  3. In positron emission tomography (PET) imaging, binding is typically estimated by fitting pharmacokinetic models to the series of measurements of radioactivity in the target tissue following intravenous injecti...

    Authors: Jonathan Tjerkaski, Simon Cervenka, Lars Farde and Granville James Matheson
    Citation: EJNMMI Research 2020 10:77
  4. We recently reported that enhanced [18F]-fluorodeoxyglucose (FDG) uptake in skeletal muscles predicts disease aggressiveness in patients with amyotrophic lateral sclerosis (ALS). The present experimental study...

    Authors: Cecilia Marini, Vanessa Cossu, Tiziana Bonifacino, Matteo Bauckneht, Carola Torazza, Silvia Bruno, Patrizia Castellani, Silvia Ravera, Marco Milanese, Consuelo Venturi, Sebastiano Carlone, Patrizia Piccioli, Laura Emionite, Silvia Morbelli, Anna Maria Orengo, Maria Isabella Donegani…
    Citation: EJNMMI Research 2020 10:76
  5. 18F-FDG PET/CT is a key molecular imaging modality to noninvasively assess and differentiate benign and malignant cardiac tumors. However, few benign cardiac tumors can be characterized by increased 18F-FDG uptak...

    Authors: En-Tao Liu, Tao-Tao Sun, Hao-Jian Dong, Si-Yun Wang, Ze-Rui Chen, Chao Liu, Dan Shao, Zhou-Yang Lian, Qiu Xie and Shu-Xia Wang
    Citation: EJNMMI Research 2020 10:75
  6. The aim of this study was to develop and validate a prognostic model incorporating [18F]FDG PET/CT radiomics for patients of minor salivary gland carcinoma (MSGC).

    Authors: Nai-Ming Cheng, Cheng-En Hsieh, Yu-Hua Dean Fang, Chun-Ta Liao, Shu-Hang Ng, Hung-Ming Wang, Wen-Chi Chou, Chien-Yu Lin and Tzu-Chen Yen
    Citation: EJNMMI Research 2020 10:74
  7. Nuclear medicine is on the constant search of precision radiopharmaceutical approaches to improve patient management. Although discordant expression of the estrogen receptor (ER) and the human epidermal growth...

    Authors: Michel Paquette, Serge Phoenix, Christine Lawson, Brigitte Guérin, Roger Lecomte, Lee-Hwa Tai, Éric E. Turcotte and Jeffrey V. Leyton
    Citation: EJNMMI Research 2020 10:69
  8. Mesenchymal stem cells (MSCs) have shown potential for treatment of different diseases. However, their working mechanism is still unknown. To elucidate this, the non-invasive and longitudinal tracking of MSCs ...

    Authors: Sarah Belderbos, Manuel Antonio González-Gómez, Frederik Cleeren, Jens Wouters, Yolanda Piñeiro, Christophe M. Deroose, An Coosemans, Willy Gsell, Guy Bormans, Jose Rivas and Uwe Himmelreich
    Citation: EJNMMI Research 2020 10:73
  9. The objective of this study was to investigate the prognostic value of 2-Deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) uptake of bone marrow (BM) and metabolic parameters of primary tumor on positron emission tomograp...

    Authors: Jeong Won Lee, Sung Yong Kim, Sun Wook Han, Jong Eun Lee, Hyun Ju Lee, Nam Hun Heo and Sang Mi Lee
    Citation: EJNMMI Research 2020 10:72
  10. Two novel methods of image reconstruction, xSPECT Quant (xQ) and xSPECT Bone (xB), that use an ordered subset conjugate gradient minimizer (OSCGM) for SPECT/CT reconstruction have been proposed. The present st...

    Authors: Noriaki Miyaji, Kenta Miwa, Ayaka Tokiwa, Hajime Ichikawa, Takashi Terauchi, Mitsuru Koizumi and Masahisa Onoguchi
    Citation: EJNMMI Research 2020 10:71
  11. Preclinical in vivo nuclear imaging of mice offers an enabling perspective to evaluate drug efficacy at optimal dose and schedule. In this study, we interrogated sufficient estrogen receptor occupancy and degr...

    Authors: Laurent Besret, Sébastien d’Heilly, Cathy Aubert, Guillaume Bluet, Florence Gruss-Leleu, Françoise Le-Gall, Anne Caron, Laurent Andrieu, Sylvie Vincent, Maysoun Shomali, Monsif Bouaboula, Carole Voland, Jeffrey Ming, Sébastien Roy, Srinivas Rao, Chantal Carrez…
    Citation: EJNMMI Research 2020 10:70
  12. In the case of extravasation of radioactive drugs used in peptide-receptor radionuclide therapy of neuroendocrine tumors, or in radionuclide therapy in general, rapid action is important to reduce or avoid com...

    Authors: Anne Kirstine Arveschoug, Anne Charlotte Bekker, Peter Iversen, Henrik Bluhme, Gerda Elisabeth Villadsen and Peter Frøhlich Staanum
    Citation: EJNMMI Research 2020 10:68
  13. Soluble epoxide hydrolase (sEH) is a promising candidate positron emission tomography (PET) imaging biomarker altered in various disorders, including vascular cognitive impairment (VCI), Alzheimer’s disease (A...

    Authors: Yong Du, Il Minn, Catherine Foss, Wojciech G. Lesniak, Feng Hu, Robert F. Dannals, Martin G. Pomper and Andrew G. Horti
    Citation: EJNMMI Research 2020 10:67
  14. [123I]epidepride is a high-affinity radiotracer used in single-photon emission computed tomography (SPECT) imaging of the D2/3 receptors. It binds with high affinity to striatal and extrastriatal receptors. Never...

    Authors: Stergios Tsartsalis, Benjamin B. Tournier and Philippe Millet
    Citation: EJNMMI Research 2020 10:66
  15. The objective of this study was to make a quantitative comparison of flortaucipir PET retention with pathological tau and β-amyloid across a range of brain regions at autopsy.

    Authors: Michael J. Pontecorvo, C. Dirk Keene, Thomas G. Beach, Thomas J. Montine, Anupa K. Arora, Michael D. Devous Sr, Michael Navitsky, Ian Kennedy, Abhinay D. Joshi, Ming Lu, Geidy E. Serrano, Lucia I. Sue, Anthony J. Intorcia, Shannon E. Rose, Angela Wilson, Leanne Hellstern…
    Citation: EJNMMI Research 2020 10:65
  16. Preclinical and clinical studies have demonstrated that immunotherapy has effectively delayed tumor progression, and the clinical outcomes of anti-PD-1/PD-L1 therapy were related to PD-L1 expression level in t...

    Authors: Sheng Zhao, Wenbin Pan, Huijie Jiang, Rongjun Zhang, Hao Jiang, Zonghui Liang and Hongbo Hu
    Citation: EJNMMI Research 2020 10:64
  17. Lanreotide is a long-acting somatostatin analogue with proven antitumour effects against well-differentiated (WD) gastroenteropancreatic-neuroendocrine tumours (GEP-NETs). However, there are no globally establ...

    Authors: Yong-il Kim, Changhoon Yoo, Seung Jun Oh, Sang Ju Lee, Junho Kang, Hee-Sang Hwang, Seung-Mo Hong, Baek-Yeol Ryoo and Jin-Sook Ryu
    Citation: EJNMMI Research 2020 10:63
  18. Focal therapies or focally escalated therapies of primary prostate cancer are becoming more and more important. This increases the need to identify the exact extension of the intraprostatic tumor and possible ...

    Authors: Thomas Franz Fassbender, Florian Schiller, Constantinos Zamboglou, Vanessa Drendel, Selina Kiefer, Cordula A. Jilg, Anca-Ligia Grosu and Michael Mix
    Citation: EJNMMI Research 2020 10:62
  19. 4-[18F] fluorobenzyl dexetimide (F-DEX) is the first non-subtype selective fluorine-18 labelled tracer for muscarinic receptors (mAChR) used in humans. A recent first-in-human study found high regional brain upta...

    Authors: Cameron D. Pain, Graeme J. O’Keefe, Uwe Ackermann, Vincent Dore, Victor L. Villemagne and Christopher C. Rowe
    Citation: EJNMMI Research 2020 10:61
  20. Quantitative analysis of brain positron-emission tomography (PET) depends on structural segmentation, which can be time-consuming and operator-dependent when performed manually. Previous automatic segmentation...

    Authors: Weiwei Ruan, Xun Sun, Xuehan Hu, Fang Liu, Fan Hu, Jinxia Guo, Yongxue Zhang and Xiaoli Lan
    Citation: EJNMMI Research 2020 10:60
  21. The radioligand [11C]VC-002 was introduced in a small initial study long ago for imaging of muscarinic acetylcholine receptors (mAChRs) in human lungs using positron emission tomography (PET). The objectives of t...

    Authors: Zsolt Cselényi, Aurelija Jucaite, Cecilia Kristensson, Per Stenkrona, Pär Ewing, Andrea Varrone, Peter Johnström, Magnus Schou, Ana Vazquez-Romero, Mohammad Mahdi Moein, Martin Bolin, Jonathan Siikanen, Pär Grybäck, Bengt Larsson, Christer Halldin, Ken Grime…
    Citation: EJNMMI Research 2020 10:59
  22. Human epidermal growth factor receptor-2 (HER2) is an essential biomarker for tumor treatment. Affibody is an ideal vector for preparing HER2 specific probes because of high affinity and rapid clearance from n...

    Authors: Yuping Xu, Lizhen Wang, Donghui Pan, Junjie Yan, Xinyu Wang, Runlin Yang, Mingzhu Li, Yu Liu and Min Yang
    Citation: EJNMMI Research 2020 10:58
  23. Perfusion CT can offer functional information about tumor angiogenesis, and 18F-FDG PET/CT quantifies the glucose metabolic activity of tumors. This prospective study aims to investigate the value of biologically...

    Authors: Kewei Zhao, Chunsheng Wang, Qingfeng Mao, Dongping Shang, Yong Huang, Li Ma, Jinming Yu and Minghuan Li
    Citation: EJNMMI Research 2020 10:57
  24. Static [18F]-F-DOPA PET images are currently used for identifying patients with glioma recurrence/progression after treatment, although the additional diagnostic value of dynamic parameters remains unknown in thi...

    Authors: Timothée Zaragori, Merwan Ginet, Pierre-Yves Marie, Véronique Roch, Rachel Grignon, Guillaume Gauchotte, Fabien Rech, Marie Blonski, Zohra Lamiral, Luc Taillandier, Laëtitia Imbert and Antoine Verger
    Citation: EJNMMI Research 2020 10:56
  25. Recent studies reported on high uptake of the PSMA ligands [68Ga]HBED-CC (68Ga-PSMA) and 18F-DCFPyL in cerebral gliomas. This study explores the regional uptake and cellular targets of 68Ga-PSMA and 18F-DCFPyL in...

    Authors: Dennis Oliveira, Carina Stegmayr, Alexander Heinzel, Johannes Ermert, Bernd Neumaier, N. Jon Shah, Felix M. Mottaghy, Karl-Josef Langen and Antje Willuweit
    Citation: EJNMMI Research 2020 10:55
  26. To compare the diagnostic sensitivity of [18F]fluoroestradiol ([18F]FES) and [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) for breast cancer recurrence in patients w...

    Authors: Sun Young Chae, Hye Joo Son, Dong Yun Lee, Eonwoo Shin, Jungsu S. Oh, Seung Yeon Seo, Sora Baek, Ji Young Kim, Sae Jung Na and Dae Hyuk Moon
    Citation: EJNMMI Research 2020 10:54
  27. Attenuation correction (AC) of PET data is usually performed using a second imaging for the generation of attenuation maps. In certain situations however—when CT- or MR-derived attenuation maps are corrupted o...

    Authors: Karim Armanious, Tobias Hepp, Thomas Küstner, Helmut Dittmann, Konstantin Nikolaou, Christian La Fougère, Bin Yang and Sergios Gatidis
    Citation: EJNMMI Research 2020 10:53
  28. PSMA-targeted radioligand therapy (PSMA-RLT) yielded impressive results in the metastasized castration-resistant prostate carcinoma (mCRPC) setting. High expression of PSMA is essential for successful PSMA-RLT...

    Authors: Florian Rosar, Kalle Ribbat, Martin Ries, Johannes Linxweiler, Mark Bartholomä, Stephan Maus, Mathias Schreckenberger, Samer Ezziddin and Fadi Khreish
    Citation: EJNMMI Research 2020 10:52
  29. Immunotherapy targeting programmed cell death 1 (PD-1) or its ligand 1 (PD-L1) has shown promising results in non-small cell lung cancer (NSCLC) patients. Exploring PD-L1 expression could help to select NSCLC ...

    Authors: Xiaodong Wu, Yan Huang, Qingping Zhao, Lei Wang, Xiao Song, Yi Li and Lei Jiang
    Citation: EJNMMI Research 2020 10:51
  30. Yoga is increasingly popular worldwide with several physical and mental benefits, but the underlying neurobiology remains unclear. Whereas many studies have focused on pure meditational aspects, the triad of y...

    Authors: June van Aalst, Jenny Ceccarini, Georg Schramm, Donatienne Van Weehaeghe, Ahmadreza Rezaei, Koen Demyttenaere, Stefan Sunaert and Koen Van Laere
    Citation: EJNMMI Research 2020 10:50
  31. Accidental peripheral nerve injury during surgical intervention results in a broad spectrum of potentially debilitating side effects. Tissue distortion and poor visibility can significantly increase the risk o...

    Authors: Junior Gonzales, Giacomo Pirovano, Chun Yuen Chow, Paula Demetrio de Souza Franca, Lukas M. Carter, Julie K. Klint, Navjot Guru, Jason S. Lewis, Glenn F. King and Thomas Reiner
    Citation: EJNMMI Research 2020 10:49
  32. New therapies to treat diabetic peripheral artery disease (PAD) require target-specific non-invasive imaging modalities to follow efficacy. As a translational study, we performed targeted imaging of receptors ...

    Authors: Lynne L. Johnson, Jordan Johnson, Ziad Ali, Yared Tekabe, Rebecca Ober, Gail Geist, Alicia McLuckie, Aram Safarov, April Holland, Geping Zhang, Marina Backer and Joseph Backer
    Citation: EJNMMI Research 2020 10:48
  33. Angiogenesis plays an important role in head and neck squamous cell carcinoma (HNSCC) progression. This pilot study was designed to compare the distribution of 68Ga-NODAGA-RGD PET/CT for imaging αvβ3 integrins in...

    Authors: Steve Durante, Vincent Dunet, François Gorostidi, Periklis Mitsakis, Niklaus Schaefer, Judith Delage and John O. Prior
    Citation: EJNMMI Research 2020 10:47
  34. Chimeric antibody Miltuximab®, a human IgG1 engineered from the parent antibody MIL-38, is in clinical development for solid tumour therapy. Miltuximab® targets glypican-1 (GPC-1), a cell surface protein invol...

    Authors: Mei-Chun Yeh, Brian W. C. Tse, Nicholas L. Fletcher, Zachary H. Houston, Maria Lund, Marianna Volpert, Chelsea Stewart, Kamil A. Sokolowski, Varinder Jeet, Kristofer J. Thurecht, Douglas H. Campbell, Bradley J. Walsh, Colleen C. Nelson and Pamela J. Russell
    Citation: EJNMMI Research 2020 10:46
  35. Prostate-specific membrane antigen (PSMA) SPECT imaging in prostate cancer (PCa) could be a valuable alternative in regions where access to PSMA-PET imaging is restricted. [99mTc]Tc-PSMA-I&S is a new 99mTc-labele...

    Authors: P. Werner, C. Neumann, M. Eiber, H. J. Wester and M. Schottelius
    Citation: EJNMMI Research 2020 10:45
  36. The molecular features of isocitrate dehydrogenase (IDH) mutation and chromosome 1p and 19q (1p/19q) codeletion status have pivotal role for differentiating gliomas and have been integrated in the World Health Or...

    Authors: Tomoya Ogawa, Nobuyuki Kawai, Keisuke Miyake, Aya Shinomiya, Yuka Yamamoto, Yoshihiro Nishiyama and Takashi Tamiya
    Citation: EJNMMI Research 2020 10:44
  37. Given the increasing clinical use of PET/MRI, potential risks to patients from simultaneous exposure to ionising radiation and (electro)magnetic fields should be thoroughly investigated as a precaution. With t...

    Authors: Gunnar Brix, Elisabeth Günther, Ute Rössler, David Endesfelder, Alexandra Kamp, Ambros Beer and Matthias Eiber
    Citation: EJNMMI Research 2020 10:43
  38. Although somatostatin receptor (SST) is a promising theranostic target and is widely expressed in tumors of various organs, the indication for therapies targeting SST is limited to typical gastroenteropancreat...

    Authors: Hyunjong Lee, Minseok Suh, Hongyoon Choi, Seunggyun Ha, Jin Chul Paeng, Gi Jeong Cheon, Keon Wook Kang and Dong Soo Lee
    Citation: EJNMMI Research 2020 10:42
  39. Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA0,TYR3-octreotate ([177Lu]Lu-DOTA-TATE) and the mechanistic target of rapamycin (mTOR) inhibitor everolimus are both approved for the treatment of n...

    Authors: Johannes Zellmer, Hsi-Yu Yen, Lena Kaiser, Erik Mille, Franz Josef Gildehaus, Guido Böning, Katja Steiger, Marcus Hacker, Peter Bartenstein, Andrei Todica, Alexander R. Haug and Harun Ilhan
    Citation: EJNMMI Research 2020 10:41
  40. Correct identification of tumour receptor status is important for treatment decisions in breast cancer. [18F]FES PET and [18F]FDHT PET allow non-invasive assessment of the oestrogen (ER) and androgen receptor (AR...

    Authors: Lemonitsa H. Mammatas, Clasina M. Venema, Carolina P. Schröder, Henrica C. W. de Vet, Michel van Kruchten, Andor W. J. M. Glaudemans, Maqsood M. Yaqub, Henk M. W. Verheul, Epie Boven, Bert van der Vegt, Erik F. J. de Vries, Elisabeth G. E. de Vries, Otto S. Hoekstra, Geke A. P. Hospers and C. Willemien Menke-van der Houven van Oordt
    Citation: EJNMMI Research 2020 10:40
  41. Schizophrenia is a disease diagnosed by visible signs and symptoms from late adolescence to early adulthood. The etiology of this disease remains unknown. An objective diagnostic approach is required. Here, we...

    Authors: Eugenia Tomasella, German Falasco, Leandro Urrutia, Lucila Bechelli, Lucia Padilla and Diego M. Gelman
    Citation: EJNMMI Research 2020 10:39
  42. Precision therapeutics continuously make advances in cancer therapy, and a field of growing interest is the combination of targeted radionuclide therapy (TRNT) with potential radiosensitizing agents. This stud...

    Authors: Anja C. L. Mortensen, Eric Morin, Christopher J. Brown, David P. Lane and Marika Nestor
    Citation: EJNMMI Research 2020 10:38
  43. Knowing the precise flow of cerebrospinal fluid (CSF) is important in the management of multiple neurological diseases. Technology for non-invasively quantifying CSF flow would allow for precise localization o...

    Authors: Hua Guo, Harikrishna Kommidi, Carl C. Lekaye, Jason Koutcher, Martin S. Judenhofer, Simon R. Cherry, Amy P. Wu, Oguz Akin, Mark M. Souweidane, Omer Aras, Zhaohui Zhu and Richard Ting
    Citation: EJNMMI Research 2020 10:37
  44. 68Ga-labelled peptides targeting somatostatin receptor 2 (SSTR2) have demonstrated encouraging results in managing patients with neuroendocrine tumours (NETs). In addition to metal chelation, bifunctional chelat....

    Authors: Yuxiao Xia, Chengrun Zeng, Yanhong Zhao, Xinyi Zhang, Zibo Li and Yue Chen
    Citation: EJNMMI Research 2020 10:36
  45. Statins are lipid-lowering agents that inhibit cholesterol synthesis and are clinically used in the primary and secondary prevention of cardiovascular diseases. However, a considerable group of patients does n...

    Authors: Gonçalo S. Clemente, Jens Rickmeier, Inês F. Antunes, Tryfon Zarganes-Tzitzikas, Alexander Dömling, Tobias Ritter and Philip H. Elsinga
    Citation: EJNMMI Research 2020 10:34
  46. Tumor hypoxia (low tissue oxygenation) is an adverse condition of the solid tumor environment, associated with malignant progression, radiotherapy resistance, and poor prognosis. One method to detect tumor hyp...

    Authors: Tengzhi Liu, Morten Karlsen, Anna Maria Karlberg and Kathrine Røe Redalen
    Citation: EJNMMI Research 2020 10:33
  47. The folate receptor alpha (FRα) is an interesting target for imaging and therapy of different cancers. We present the first in-human radiation dosimetry and radiation safety results acquired within a prospecti...

    Authors: Silvano Gnesin, Joachim Müller, Irene A. Burger, Alexander Meisel, Marco Siano, Martin Früh, Matthias Choschzick, Cristina Müller, Roger Schibli, Simon M. Ametamey, Philipp A. Kaufmann, Valerie Treyer, John O. Prior and Niklaus Schaefer
    Citation: EJNMMI Research 2020 10:32
  48. To investigate the added value and diagnostic accuracy of 68Ga-PSMA PET/CT versus bone scintigraphy (BS) for bone metastasis detection at the primary staging of prostate cancer (PCa).

    Authors: Helle D. Zacho, Søren Ravn, Ali Afshar-Oromieh, Joan Fledelius, June A. Ejlersen and Lars J. Petersen
    Citation: EJNMMI Research 2020 10:31
  49. Multimodal PET/MRI image data simultaneously obtained from patients with early-stage of Alzheimer’s disease (eAD) were assessed in order to observe pathophysiologic and functional changes, as well as alteratio...

    Authors: Hidehiko Okazawa, Masamichi Ikawa, Minyoung Jung, Rikiya Maruyama, Tetsuya Tsujikawa, Tetsuya Mori, Mahmudur G. M. Rahman, Akira Makino, Yasushi Kiyono and Hirotaka Kosaka
    Citation: EJNMMI Research 2020 10:30

EANM'24 - Future Congress!

EANM'24 banner horizontal

Future Congress

37th Annual Congress of the European Association of Nuclear Medicine

October 19 – 23, 2024
Hamburg, Germany


CCH – Congress Center Hamburg
Congressplatz 1
20355 Hamburg, Germany
URL: https://www.cch.de/en/

The EJNMMI Journal Family and EANM Springer Award

New Content Item

EJNMMI is part of the EJNMMI Journal Family. Highlights of our featured content and the latest developments from the EJNMMI group of journals can be found on the EJNMMI Journal Family webpage. There you find details about the annual EANM Springer Prize.


Do you want to publish your paper open access?

Details of the OpenChoice option in EJNMMI are available in the submission guidelines.

If your institution has a Read and Publish (Springer Compact) agreement, you may publish your article open access at no cost to you. In addition, you can enjoy full access to all Springer subscription journal content.

Please check the agreement details by participating country here.